NDLI: Maximal androgen blockade for advanced prostate cancer.

Please wait, while we are loading the content...

Year: 2016 Volume: 30

Year: 2015 Volume: 29

Year: 2014 Volume: 28

Year: 2013 Volume: 27

Year: 2012 Volume: 26

Year: 2011 Volume: 25

Year: 2010 Volume: 24

Year: 2009 Volume: 23

Year: 2008 Volume: 22

Year: 2008 Volume: 22 Issue: 6

Year: 2008 Volume: 22 Issue: 5

Year: 2008 Volume: 22 Issue: 4

Year: 2008 Volume: 22 Issue: 3

Year: 2008 Volume: 22 Issue: 2

Endocrinology and the prostate. Preface.

Androgen biosynthetic pathways in the human prostate.

Expression of steroidogenic enzymes and sex-steroid receptors in human prostate.

Intra-prostatic androgen levels during various androgen-blockade regimens.

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.

Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate.

Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma.

Androgen deprivation therapy for precancerous lesions of the prostate.

Current status and prospects of androgen depletion therapy for prostate cancer.

Primary combined androgen blockade in localized disease and its mechanism.

The benefits of early androgen blockade.

Maximal androgen blockade for advanced prostate cancer.

Mechanisms of bone metastasis in prostate cancer: clinical implications.

A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Mechanisms of prostate cancer progression to androgen independence.

5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

Year: 2008 Volume: 22 Issue: 1

Year: 2007 Volume: 21

Maximal androgen blockade for advanced prostate cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Klotz, Laurence
Description	Country affiliation: Canada Author Affiliation: Klotz L ( Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, ON, Canada. laurence.klotz@sunnybrook.ca)
Abstract	Maximal androgen blockade (MAB) refers to the combination of medical (gonadotrophin-releasing hormone agonist) or surgical castration with an anti-androgen for the treatment of advanced prostate cancer. A substantial body of basic research has improved our understanding of the interactions between the anti-androgens, the androgen receptor, and androgen response elements in the genome. Anti-androgens act by two primary mechanisms: inhibition of ligand (androgen) binding to the androgen receptor, and inhibition of androgen-independent activation of the receptor. The latter mechanism occurs via several pathways, including inhibiting nuclear co-activators, activating co-suppressors, and inhibiting transcription of a variety of androgen-regulated genes. It is more accurate to refer to these compounds as androgen-receptor antagonists, since they inhibit activation whether this is androgen-mediated or not. Within the class of non-steroidal anti-androgens, there is variation in the degree to which ligand-independent activation is inhibited. Over the last 25 years, approximately 30 clinical trials have addressed the benefit of MAB versus monotherapy. Most of these trials have evaluated flutamide or nilutamide. Several meta-analyses suggest a modest survival benefit of these drugs, amounting to an 8% mortality reduction at 5 years. Preclinical data and two randomized trials -- one historic and one current -- suggest that bicalutamide may be a more effective drug in this respect. This requires confirmation pending further maturity of the current trial, which is the only one directly comparing bicalutamide plus castration to castration alone. In prostate cancer patients at high risk for mortality (based on extent of disease or prostate-specific antigen kinetics), combination therapy with bicalutamide should be considered in preference to monotherapy.
File Format	HTM / HTML
ISSN	1521690X
Issue Number	2
Volume Number	22
e-ISSN	18781594
Journal	Best Practice & Research Clinical Endocrinology & Metabolism
Language	English
Publisher	Elsevier
Publisher Date	2008-04-01
Publisher Place	Netherlands
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Metabolism Discipline Endocrinology Androgen Antagonists Administration & Dosage Prostatic Neoplasms Drug Therapy Adverse Effects Economics Anilides Antineoplastic Agents, Hormonal Antineoplastic Combined Chemotherapy Protocols Therapeutic Use Combined Modality Therapy Disease Progression Dose-response Relationship, Drug Humans Male Meta-analysis As Topic Neoplasm Staging Neoplasms, Hormone-dependent Nitriles Orchiectomy Methods Mortality Pathology Randomized Controlled Trials As Topic Survival Analysis Tosyl Compounds Withholding Treatment Evaluation Studies Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Endocrinology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in